Trial Profile
Phase II Study of Low-Dose Intravenous Decitabine in Patients Aged greater than 60 Years With Acute Myeloid Leukemia Who Are Not Eligible for Standard Induction Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 01 Jul 2020 Results (n=177) evaluating clinical features and outcomes associated with chromosome 17p loss or TP53 gene mutations in older, unfit DAC-treated AML patients, published in the Annals of Hematology
- 02 Sep 2011 New source identified and integrated (Germany Clinical Trials Registry).
- 27 Mar 2009 New trial record